nach oben

16.10.2017 | Original Article | Ausgabe 3/2018

Simultaneous whole-body ¹⁸F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

Zeitschrift:: European Journal of Nuclear Medicine and Molecular Imaging > Ausgabe 3/2018

Autoren:: Martin T. Freitag, Claudia Kesch, Jens Cardinale, Paul Flechsig, Ralf Floca, Matthias Eiber, David Bonekamp, Jan P. Radtke, Clemens Kratochwil, Klaus Kopka, Markus Hohenfellner, Albrecht Stenzinger, Heinz-Peter Schlemmer, Uwe Haberkorn, Frederik Giesel

Abstract

Introduction

The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body ¹⁸F–PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients.

Methods

Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after ¹⁸F–PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUV_mean-quantification was performed using a 3D–isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0).

Results

The examinations were well accepted by patients and comprised 1 h. SUV_mean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of ¹⁸F–PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results.

Conclusions

The presented ¹⁸F–PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

★ PREMIUM-INHALT

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt gratis testen * Jetzt kaufen

Sie können e.Med Interdisziplinär 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Jetzt testen ¹

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. CrossRefPubMed

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. CrossRefPubMed

Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. CrossRefPubMed

Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4022–8. CrossRef

Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:3036–43. CrossRef

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7645–53. CrossRef

Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. ¹⁸F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2015;56:1003–10.

Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2015;17:565–74. CrossRef

Cardinale J, Schafer M, Benešova M, Bauder-Wust U, Leotta K, Eder M, et al. Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2017;58:425–31. CrossRefPubMed

10.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. CrossRefPubMed

11.

Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776–87. CrossRefPubMed

12.

Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. CrossRefPubMed

13.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36. CrossRefPubMed

14.

Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83. CrossRefPubMed

15.

Freitag MT, Fenchel M, Bäumer P, Heußer T, Rank CM, Kachelrieß M, et al. Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. Eur J Radiol. 2017;96:12–20.

16.

Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol. 2016;69:16–40. CrossRefPubMed

17.

Biederer J. MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging. 2008;8:125–30. CrossRefPubMedPubMedCentral

18.

Wallis CJD, English JC, Goldenberg SL. The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J. 2011;5:e104–8. CrossRefPubMedPubMedCentral

19.

Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, et al. The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190:1728–34. CrossRefPubMed

20.

Radtke JP, Hadaschik BA, Wolf MB, Freitag MT, Schwab C, Alt C, et al. The impact of magnetic resonance imaging on prediction of extraprostatic extension and prostatectomy outcome in patients with low-, intermediate- and high-risk prostate cancer: try to find a standard. J Endourol. 2015;29:1396–405. CrossRefPubMed

21.

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner M, Katayama S, et al. (68)Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med Off Publ Soc Nucl Med. 2017.

22.

Lederer CM, Shirley VS, Browne E, editors. Table of isotopes. 7th ed. New York: Wiley; 1978.

23.

Hong I, Rothfuss H, Fürst S, Michel C, Nekolla SG, Bendriem B, et al. Prompt gamma correction for Ga-68 PSMA PET studies. IEEE Xplore [Internet]. 2015; Available from: http://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=7582166. Accessed 2017–04-02.

24.

Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer H-P, et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS One. 2017;12:e0183329. CrossRefPubMedPubMedCentral

25.

Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelrieß M, Gnirs R, Kopka K, et al. Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. Eur J Nucl Med Mol Imaging. 2017.

26.

Blumhagen JO, Ladebeck R, Fenchel M, Scheffler K. MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE). Magn Reson Med. 2013;70:1047–57. CrossRefPubMed

27.

Rezaei A, Salvo K, Vahle T, Panin V, Casey M, Boada F, et al. Plane-dependent ML scatter scaling: 3D extension of the 2D simulated single scatter (SSS) estimate. Phys Med Biol. 2017;62:6515–31. CrossRefPubMed

Titel: Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study
Autoren:: Martin T. Freitag
Claudia Kesch
Jens Cardinale
Paul Flechsig
Ralf Floca
Matthias Eiber
David Bonekamp
Jan P. Radtke
Clemens Kratochwil
Klaus Kopka
Markus Hohenfellner
Albrecht Stenzinger
Heinz-Peter Schlemmer
Uwe Haberkorn
Frederik Giesel
Publikationsdatum: 16.10.2017
DOI: https://doi.org/10.1007/s00259-017-3854-6
Verlag: Springer Berlin Heidelberg
Zeitschrift: European Journal of Nuclear Medicine and Molecular Imaging
Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089

Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.
Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Radiologie

e.Med Onkologie

Weitere Artikel der Ausgabe 3/2018

Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia

Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT

Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide